Cytisinicline + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Smoking Cessation

Conditions

Smoking Cessation

Trial Timeline

Oct 13, 2020 → Dec 23, 2021

NCT ID

NCT04576949

About Cytisinicline + Placebo

Cytisinicline + Placebo is a phase 3 stage product being developed by Achieve Life Sciences for Smoking Cessation. The current trial status is completed. This product is registered under clinical trial identifier NCT04576949. Target conditions include Smoking Cessation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07392125	Phase 3	Recruiting	May 15, 2026	Sep 30, 2027	Vaping Cessation
NCT05431387	Phase 2	Completed	Jul 13, 2022	Feb 28, 2023	Vaping
NCT05206370	Phase 3	Completed	Jan 20, 2022	Mar 21, 2023	Smoking Cessation
NCT04576949	Phase 3	Completed	Oct 13, 2020	Dec 23, 2021	Smoking Cessation

Competing Products

20 competing products in Smoking Cessation

See all competitors

Product	Company	Stage	Hype Score
Brenipatide + Placebo	Eli Lilly	Phase 2	52
Nicotine + Nicotine + Nicotine	Johnson & Johnson	Phase 2	52
Nicotine replacement therapy + Nicotine replacement therapy	Johnson & Johnson	Phase 2	52
Nicotine Patch + Placebo Patch	Johnson & Johnson	Phase 1	33
Nicotine Patch + Placebo Patch + SLS Comparator Patch	Johnson & Johnson	Phase 1	33
Nicotine + Placebo	Johnson & Johnson	Pre-clinical	23
Nicotine Patch + Nicotine Patch Comparator + Placebo Patch	Johnson & Johnson	Phase 1	33
Nicotine Patch + Placebo Patch + No Patch Control	Johnson & Johnson	Phase 1	33
Nicotine gum + Placebo gum + Nicotine inhaler + Placebo inhaler	Johnson & Johnson	Phase 3	77
Nicotine patch, nicotine inhaler, bupropion + Nicotine patch	Johnson & Johnson	Approved	85
AZD4041 + Placebo	AstraZeneca	Phase 1	33
taranabant	Merck	Phase 2	52
Nicotine replacement therapy	Novartis	Pre-clinical	23
AFQ065	Novartis	Phase 1	33
Liraglutide + Placebo	Novo Nordisk	Phase 2	51
Varenicline	Pfizer	Phase 2	51
placebo + Varenicline Tartarate	Pfizer	Phase 3	76
varenicline + placebo	Pfizer	Approved	84
varenicline (CP-526,555)	Pfizer	Phase 3	76
placebo + varenicline	Pfizer	Approved	84

Other Products from Achieve Life Sciences

Custirsen + Docetaxel + Prednisone + DexamethasonePhase 3

Custirsen + DocetaxelPhase 3

Cytisinicline + PlaceboPhase 3

Taxol + TOCOSOL PaclitaxelPhase 3

custirsen sodium + isotonic, 0.9% sodium chloride + docetaxel + cabazitaxel + prednisonePhase 3